The present invention relates to racemic ilaprazole, 2 - [[(4-methoxy-3-methyl) -2-pyridinyl] - methyl] sulfonyl] -5- (1 Hydrogen - pyrrolidin -1 - yl) -1 Hydrogen - benzimidazole-crystal form; The present inve
The invention relates to crystalline forms of racemic ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a crystalline Form of ilaprazole ...
CONSTITUTION: A crystalline form of racemic illaprazole has 156.1, 143.2, 110.6, and 10.5 ppm of peak at solid phase 13C CP/MAS NMR. The crystalline form has starting temperature at 170C. The crystalline form has 9.4o2 0.2o2, 17.5o2 0.2o2, 18.8o2 0.2o2, and 32.8o2 0.2o2 of peak at...
The invention relates to crystalline forms of racemic ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a crystalline Form of ilaprazole ...
Solid state forms of racemic ilaprazoleA crystalline form of racemic ilaprazole characterized by a NMR spectrum 13C CP / MAS estadosólido having peaks at 139.1, 127.4, 124.1 and 12.6.BRACKETT, JOHNPARENT, STEPHANSHEN, JINYUJONAITIS, DAVID
The invention relates to crystalline forms of racemic ilaprazole, 2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]sulfinyl]-5-(1H-pyrrol-1-yl) 1H-Benzimidazole. The invention also relates to a pharmaceutical composition for inhibiting gastric acid secretion comprising a crystalline Form of ilaprazole ...
Disclosed is a crystalline form of racemic ilaprazole which has a solid state 13C CP/MAS NMR spectra having peaks at 139.1, 127.4, 124.1 and 12.6. Also disclosed is the use of the crystalline form of racemic ilaprazole for preparing a medicament for treating a gastrointestinal inflammatory ...
FIELD: chemistry.;SUBSTANCE: present invention relates to crystalline forms A, B and F of racemic ilaprazole (2[[(4-methoxy-3-methyl-2-pyridinyl)-methyl]thionyl]-5-(1H-pyrrol-1-yl)-1H-benzimidazole). The invention also relates to a pharmaceutical composition based on crystalline ilaprazole ...